Background The effectiveness of CN is still uncertain despite two significant trials, SURTIME
and CARMENA, which aimed to demonstrate its benefits for mccRCC. These trials …

4552 Background: The role of CN remains questionable after the well intentioned two large
prospective trials, SURTIME AND CARMENA, failed to show the benefit of CN for mccRCC …

Nephrectomy for patients with primary metastatic clear cell renal cell carcinoma (MccRCC)
has been discussed for decades. Just after the millennium, two studies demonstrated a …

Importance Level I evidence has failed to demonstrate an overall survival (OS) advantage
for cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma …

Objectives Despite immune checkpoint inhibitor (ICI) approval for metastatic renal cell
carcinoma (mRCC) in 2015, cytoreductive nephrectomy (CN) is guided by extrapolation from …

Background About 20% of patients with renal cell carcinoma present with non-clear cell
histology (nccRCC), encompassing various histological types. While surgery remains pivotal …

TPS490 Background: The role of cytoreductive nephrectomy (CN) in the treatment of
metastatic renal cell carcinoma (mRCC) remains unclear in the immuno-oncology (IO) era …

Discussion The landscape of mRCC has been rapidly evolving over the past several years,
as has the data surrounding the applicability of CN in the modern era. The phase III …

Purpose The prospective CARMENA trial surprisingly suggested that patients with upfront
metastatic clear-cell renal cell carcinoma (m-ccRCC) would not benefit from cytoreductive …

Introduction A recent randomized trial questioned the role of cytoreductive nephrectomy in
clear-cell metastatic renal cell carcinoma (ccmRCC). We reassessed the effect of …